Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

9.62p
   
  • Change Today:
    -0.083p
  • 52 Week High: 18.35
  • 52 Week Low: 8.80
  • Currency: UK Pounds
  • Shares Issued: 139.47m
  • Volume: 13,141
  • Market Cap: 13.41m
  • RiskGrade: 349
  • Beta: 0.02

Immupharma Overview

Immupharma is in the pharma and biotech sector and is currently trading at 9.62p per share. In the last year Immupharma's share price has ranged from 8.80p to 18.35p and brokers are currently rating this stock as 'strong sell'.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -9941.0% -4900.0%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 166.4 135.3
Pr/Book 1.8  
Latest F'cast
Revenue -46.0% 23.0%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Immupharma Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-14 0.18 (3.34) (3.43)p n/a n/a n/a n/a 0.0%
31-Dec-15 0.08 (4.55) (4.40)p n/a n/a n/a n/a 0.0%
31-Dec-16 0.16 (6.31) (4.54)p n/a n/a n/a n/a 0.0%
31-Dec-17 0.15 (7.00) (4.75)p n/a n/a n/a n/a 0.0%
31-Dec-18 0.08 (7.96) (5.19)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Immupharma Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 0.10 (4.90) (2.90)p n/a n/a n/a n/a 0.0%
31-Dec-20 0.10 (5.10) (2.80)p n/a n/a n/a n/a 0.0%

Copyright © 2019 FactSet Research Systems Inc. All rights reserved.

Immupharma Company Announcements

Second Price Monitoring Extn 07-Oct-2019 12:07 RNS
Price Monitoring Extension 07-Oct-2019 12:02 RNS
Second Price Monitoring Extn 04-Oct-2019 12:07 RNS

Latest Immupharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Immupharma Market Data

Currency UK Pounds
Share Price 9.62p
Change Today -0.083p
% Change -0.86 %
52 Week High 18.35
52 Week Low 8.80
Volume 13,141
Shares Issued 139.47m
Market Cap 13.41m
Beta 0.02
RiskGrade 349

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.27% below the market average35.27% below the market average35.27% below the market average35.27% below the market average35.27% below the market average
34.48% above the sector average34.48% above the sector average34.48% above the sector average34.48% above the sector average34.48% above the sector average
Price Trend
62.01% below the market average62.01% below the market average62.01% below the market average62.01% below the market average62.01% below the market average
35.59% below the sector average35.59% below the sector average35.59% below the sector average35.59% below the sector average35.59% below the sector average
Income Not Available
Growth
38.06% below the market average38.06% below the market average38.06% below the market average38.06% below the market average38.06% below the market average
83.78% below the sector average83.78% below the sector average83.78% below the sector average83.78% below the sector average83.78% below the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 0
Sell 0
Strong Sell 1
Total 1
strong_sell
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Immupharma Dividends

No dividends found

Trades for 14-Oct-2019

Time Volume / Share Price
08:24 2,110 @ 9.62p
08:20 1,031 @ 9.60p
08:05 10,000 @ 9.62p

Immupharma Key Personnel

CEO Dimitri Dimitriou

Top of Page